Peptic Ulcer Disease (PUD) remains a prevalent gastroenterological disorder, with significant morbidity and mortality. Despite advances in understanding its pathophysiology and the availability of effective treatments, the management of PUD continues to pose challenges. This article will discuss modern strategies for the effective management of PUD.
Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary causes of PUD. Both disrupt the gastric mucosal defense and repair systems, leading to ulcer formation. Recent studies also suggest a genetic predisposition, further complicating the disease's pathophysiology.
Endoscopy with biopsy remains the gold standard for diagnosing PUD. However, non-invasive tests such as urea breath test, stool antigen test, and serology are increasingly used due to their convenience and cost-effectiveness.
The mainstay of PUD treatment is the eradication of H. pylori, achieved through a combination of proton pump inhibitors and antibiotics. The choice of antibiotics should be guided by local antibiotic resistance patterns. For NSAID-induced ulcers, discontinuation of the offending drug and use of proton pump inhibitors are recommended. Adjunctive therapies such as antacids and sucralfate can provide symptomatic relief but do not contribute to ulcer healing.
Emerging strategies include the use of probiotics to modulate the gut microbiota and the development of vaccines against H. pylori. Research is also underway to identify genetic markers for PUD to enable personalized treatment plans.
Effective management of PUD requires a comprehensive approach that includes understanding the pathophysiology, making an accurate diagnosis, and implementing appropriate treatment strategies. As we continue to decode PUD, it is hoped that new insights will lead to more effective and personalized treatments for this common and potentially serious condition.
1.
Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.
2.
Long-Acting Interferon Therapy Approved for ET
3.
More cancer cases in areas where incarceration rates are high: Study
4.
Firefighters who eat better can combat cancer.
5.
Second opinions don't significantly delay breast cancer treatment
1.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
2.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
3.
Unlocking the Potential of Plinabulin: A New Frontier in Cancer Treatment
4.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
5.
Regenerative Reprogramming of Dormant Cellular Niches Following Cancer Therapy
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Hands-on Workshop: Hematology
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation